Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by K.M. Ardeshna
Analysis of Efficacy and Safety of Loncastuximab Tesirine (Adct-402) by Demographic and Clinical Characteristics in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma
American Journal of Hematology
Hematology
Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma
Current Oncology
Oncology
Bone Marrow Molecular Markers Associated With Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma
BioMed Research International
Immunology
Molecular Biology
Biochemistry
Microbiology
Medicine
Genetics
Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Annals of Hematology
Medicine
Hematology
Molecular Landscape of Relapse/Refractory Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase Iia Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
